COMMUNIQUÉS West-GlobeNewswire
-
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/04/2026 -
ANNA Autism Care Appoints Ariana Boutain, PhD, BCBA-D as Chief Clinical Officer
06/04/2026 -
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference
06/04/2026 -
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital
06/04/2026 -
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
06/04/2026 -
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer
06/04/2026 -
Kraig Biocraft Laboratories Shatters Production Record, Delivering Over 1.3 Metric Tons of Spider Silk Cocoons in a Single Month, A 5X Increase Over Previous High
06/04/2026 -
Sharps Technology Reports 2025 Year-End Results and Highlights Continued Execution of Solana Treasury Strategy
06/04/2026 -
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
06/04/2026 -
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
06/04/2026 -
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application
06/04/2026 -
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
06/04/2026 -
Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its Pointillist Platform
06/04/2026 -
Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention
06/04/2026 -
Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor
06/04/2026 -
Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform
06/04/2026 -
Beacon Biosignals Upsizes Series B Financing to Over $97 Million
06/04/2026 -
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/04/2026 -
MEDVi QUAD Claims Evaluated: Real Online Doctor-Approval ED Medication for Men's Sexual Performance
04/04/2026
Pages